ACHL
NASDAQAchilles Therapeutics plc
Latest news
25 items- SECSEC Form 15-12G filed by Achilles Therapeutics plc15-12G - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form 6-K filed by Achilles Therapeutics plc6-K - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form S-8 POS filed by Achilles Therapeutics plcS-8 POS - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form S-8 POS filed by Achilles Therapeutics plcS-8 POS - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form S-8 POS filed by Achilles Therapeutics plcS-8 POS - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form S-8 POS filed by Achilles Therapeutics plcS-8 POS - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form EFFECT filed by Achilles Therapeutics plcEFFECT - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form POS AM filed by Achilles Therapeutics plcPOS AM - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form 25 filed by Achilles Therapeutics plc25 - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form 6-K filed by Achilles Therapeutics plc6-K - Achilles Therapeutics plc (0001830749) (Filer)
- PRAchilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC DeregistrationLONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and its intent to deregister its ADSs from the Securities and Exchange Commission (SEC) under Section 12(b) of the Securities Exchange Act of 1934 (Exchange Act). As previously reported, the Company has called a General Meeting for March 20, 2025 to obtain shareholder approval to commence a members' voluntary liquidation. The planned delisting of the ADSs is being undertaken in connection with the contemplated liquidation. Th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Achilles Therapeutics plcSCHEDULE 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
- SECSEC Form 144 filed by Achilles Therapeutics plc144 - Achilles Therapeutics plc (0001830749) (Subject)
- SECSEC Form 144 filed by Achilles Therapeutics plc144 - Achilles Therapeutics plc (0001830749) (Subject)
- SECSEC Form 144 filed by Achilles Therapeutics plc144 - Achilles Therapeutics plc (0001830749) (Subject)
- SECSEC Form 144 filed by Achilles Therapeutics plc144 - Achilles Therapeutics plc (0001830749) (Subject)
- SECSEC Form 144 filed by Achilles Therapeutics plc144 - Achilles Therapeutics plc (0001830749) (Subject)
- SECSEC Form 6-K filed by Achilles Therapeutics plc6-K - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form 6-K filed by Achilles Therapeutics plc6-K - Achilles Therapeutics plc (0001830749) (Filer)
- SECSEC Form 6-K filed by Achilles Therapeutics plc6-K - Achilles Therapeutics plc (0001830749) (Filer)
- PRAchilles Therapeutics Announces Sale of Technology Assets to AstraZeneca- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (NASDAQ:AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Professor Charles Swanton at University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data
- SECSEC Form 6-K filed by Achilles Therapeutics plc6-K - Achilles Therapeutics plc (0001830749) (Filer)
- PRAchilles Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketLONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024. The transfer of the Company's listing to the Nasdaq Capital Market is not expected to have any impact on trading in the Company's ADSs. The Company's ADSs will continue to trade under the symbol "ACHL." The approval by Nasdaq w
- 13D/GAmendment: SEC Form SC 13G/A filed by Achilles Therapeutics plcSC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)
- SECSEC Form 6-K filed by Achilles Therapeutics plc6-K - Achilles Therapeutics plc (0001830749) (Filer)
ACHL FAQ
7 questionsWhat does Achilles Therapeutics plc do?
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder...Where does ACHL stock trade?
Achilles Therapeutics plc (ACHL) is listed on NASDAQ.What sector and industry is ACHL in?
Achilles Therapeutics plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Achilles Therapeutics plc go public?
Achilles Therapeutics plc (ACHL) completed its IPO in 2021.What are analysts saying about ACHL?
Achilles Therapeutics plc has had 1 recent analyst action on file. The most recent action was from Piper Sandler: Neutral with a $200.00 price target on 2024-04-05. Recent price targets cluster around $200.00.What companies are similar to ACHL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ACHL side-by-side with any of them on Quantisnow.How can I track ACHL on Quantisnow?
Quantisnow aggregates Achilles Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACHL to receive live email and push alerts on every new disclosure.